Biotech Values

[DewDiligence]

BMY presents phase-2 Milvexian data at AHA:

https://www.businesswire.com/news/home/20211115005987/en

Milvexian is an oral anticoagulant that inhibits Factor XIa, a new MoA. Compared to FXa inhibitors such as Eliquis and Xarelto, Milvexian may be able to offer comparable efficacy with less bleeding risk.

BMY is developing Milvexian with JNJ, pursuant to a 2018 collaboration (#msg-140083631). BMY hopes Milvexian can replace some or all of the revenue from Eliquis, which loses exclusivity in 2028. Phase-3 trials for Milvexian are slated to start in 2022.